Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Nanoparticles in porous microparticles (NPinPMP), a novel delivery system for sustained delivery of protein drugs, was developed using supercritical infusion and pressure quench technology, which does not expose proteins to organic solvents or sonication. The delivery system design is based on the ability of supercritical carbon dioxide (SC CO2) to expand poly(lactic-co-glycolic) acid (PLGA) matrix but not polylactic acid (PLA) matrix. The technology was applied to bevacizumab, a protein drug administered once a month intravitreally to treat wet age related macular degeneration. Bevacizumab coated PLA nanoparticles were encapsulated into porosifying PLGA microparticles by exposing the mixture to SC CO2. After SC CO2 exposure, the size of PLGA microparticles increased by 6.9-fold. Confocal and scanning electron microscopy studies demonstrated the expansion and porosification of PLGA microparticles and infusion of PLA nanoparticles inside PLGA microparticles. In vitro release of bevacizumab from NPinPMP was sustained for 4 months. Size exclusion chromatography, fluorescence spectroscopy, circular dichroism spectroscopy, SDS-PAGE, and ELISA studies indicated that the released bevacizumab maintained its monomeric form, conformation, and activity. Further, in vivo delivery of bevacizumab from NPinPMP was evaluated using noninvasive fluorophotometry after intravitreal administration of Alexa Fluor 488 conjugated bevacizumab in either solution or NPinPMP in a rat model. Unlike the vitreal signal from Alexa-bevacizumab solution, which reached baseline at 2 weeks, release of Alexa-bevacizumab from NPinPMP could be detected for 2 months. Thus, NPinPMP is a novel sustained release system for protein drugs to reduce frequency of protein injections in the therapy of back of the eye diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Issues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386
Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms
Houchin, M. L., & Topp, E. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21176 · Cited by 277
Crotts, G., & Park, T. G. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809008253 · Cited by 263
Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations
Short, B. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310955 · Cited by 244
Koushik, K., & Kompella, U. B. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019308.25479.a4 · Cited by 86
Self-citation
Cited by
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics
Ding, D., & Zhu, Q. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.036 · Cited by 386
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications
Kankala, R. K., Zhang, Y. S., Wang, S., Lee, C., & Chen, A. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700433 · Cited by 285
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Self-citation
Metadata
- Authors
- Yandrapu, S. K., Upadhyay, A. K., Petrash, J. M., & Kompella, U. B.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-11-12
- Volume
- 10
- Issue
- 12
- Pages
- 4676-4686
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2072544476
- Cited by
- 99
- References
- 8
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab. https://app.cochat.ai/papers/10.1021/mp400487f
- The paper
- Yandrapu, S. K., Upadhyay, A. K., Petrash, J. M., & Kompella, U. B. (2013). Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab. Molecular Pharmaceutics. https://doi.org/10.1021/mp400487f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.